News for Providers
Top stories summarized by our editors
9/21/2018

An analysis of data for 6,574 youths with presumed end-stage kidney disease who initiated dialysis before the age of 15 found kidney function recovery was uncommon. Recovery was associated with conditions such as hemolytic uremic syndrome, ischemic kidney failure and vasculitis, according to the study in the Clinical Journal of the American Society of Nephrology.

More Summaries:
kidney disease, ESKD
9/21/2018

HHS said the Trump administration is working with California-based drugmaker Opiant Pharmaceuticals to develop a nasal spray opioid overdose antidote called nalmefene that can be used to prevent opioid-related deaths and protect against the threat of fentanyl being used in a terrorist attack. An injector version of the drug was approved by the FDA, but it was pulled from the market in 2008 due to low sales.

9/21/2018

In its Morbidity and Mortality Weekly Report, the CDC said an outbreak of antibiotic-resistant Campylobacter infections that affected 118 individuals in 18 states from January 2017 to February of this year was linked to puppies sold at pet stores. All but seven of the 149 puppies investigators examined had received at least one course of antibiotics, and researchers said similar outbreaks are possible in the future.

More Summaries:
CDC
9/21/2018

Teens with chronic illnesses who received alcohol-interactive drugs were 43% less likely to have drunk alcohol in the previous year and had reduced overall alcohol intake compared with those who weren't on alcohol-interactive medications, researchers reported in Pediatrics. "Youth who are living with a chronic illness are motivated to keep their condition under control -- and well managed. We need to build on that," said researcher Dr. Elissa Weitzman.

9/21/2018

A report in The Lancet found more than half of the 193 United Nations member states that signed on to the Sustainable Development Goals blueprint will fail to reach targets to reduce premature deaths from cancer, cardiovascular disease, chronic respiratory disease and diabetes by 2030. The goals include 17 target categories in areas such as poverty, hunger, quality education, good health and well-being.

Full Story:
CNN
More Summaries:
UN
9/21/2018

A study in the journal Stroke found that the Mediterranean diet was associated with a 22% reduced risk for strokes in women compared to a 6% drop for men. Researchers collected data from more than 23,000 men and women between the ages of 40 and 77 for 17 years.

More Summaries:
stroke
9/21/2018

Researchers at Children's National Health System found adhering to standardized feeding practices for very low birth weight babies helped to increase weight gain. The study, to be presented at the Virginia Neonatal Nutrition Association conference, noted the feeding strategies included ensuring adequate calorie, protein and micronutrient intake and maximizing use of the mother's breast milk.

9/21/2018

An initial public offering pulled in $96 million for cancer biotech company Y-mAbs Therapeutics. The company intends to file biologics license applications for two pediatric neuroblastoma candidates that both already have orphan drug, rare pediatric disease and breakthrough therapy designations.

Full Story:
BioCentury
More Summaries:
Y-mAbs Therapeutics
9/21/2018

Daiichi Sankyo and a subsidiary of Merck, known as MSD outside North America, agreed to work together to develop the former's DS-8201 in combination with the latter's Keytruda as a treatment for patients with breast or lung cancers. Daiichi will conduct a two-part Phase Ib safety and efficacy study of the combination drug in patients with HER2-expressing or HER2 mutant advanced/metastatic non-small cell lung cancer and patients with HER2-expressing advanced/metastatic breast cancer.

9/21/2018

Astellas Pharma announced that the key endpoints were met for its Phase III study to evaluate its candidate roxadustat as a treatment for patients with chronic kidney disease and anemia who were not undergoing dialysis. Data showed that the drug was superior in efficacy compared to placebo based on hemoglobin response rate during the first 24 weeks and changes in baseline hemoglobin from weeks 28 to 52.

More Summaries:
Astellas Pharma